In the next issue of Pharma Technology Focus, we explore the complex topic of personalised medicine, which looks set to bring an end to the one-size-fits-all approach to traditional medicine. In order to bring these benefits from concept to reality, the pharma industry and supply chain will have to embrace dramatic changes in manufacturing methods, as drug makers switch from producing large batches to small and customised supplies. We find out what needs to change to facilitate the rise of precision medicine.

Also in this special issue, we find out about the economics of CAR-T therapy. While CAR-T looks set to revolutionise and individualise the treatment of cancer, will the world be able to afford the price tag on one of the industry’s most advanced – and expensive – therapies?

Plus, we take a look at a new platform which uses AI to optimise drug combination therapy, and examine the importance of microbiome in precision medicine. Could a better understanding of the community of bacteria, viruses and microorganisms that inhabit the human body supplant genetics as the primary target for precision medicine?